SlideShare a Scribd company logo

Chander slides november 19 20 2015-toronto

•
•
Canadian Organization for Rare Disorders
Canadian Organization for Rare Disorders

Expert Patient Advocates & 21st Century Therapies Forum Nov 19 - 20, 2015

Government & Nonprofit
1 of 14
Download to read offline
Expert Patient Advocates & 21st Century Therapies Forum TORONTO NOVEMBER 19-20, 2015 CHANDER SEHGAL, MD, MBA DIRECTOR, CDR AND OPTIMAL USE
Role of CADTH Health  Canada  asks:   Is  it  safe?  Does  it   work?   Patented  Medicine  Prices     Review  Board  asks:   Is  the  price  excessive   compared  to  other   developed  countries?     CADTH  asks:    How  does  it   compare  to   exis>ng     treatment  op>ons?   Federal,   provincial  &   territorial  health   bodies  ask:   Can  we  afford   it?    
18 publicly funded drug plans serving  7.8  million  people   1 pan-Canadian* process: Conducting reviews of the clinical, cost-effectiveness, and patient group input for drugs Providing evidence-based formulary listing recommendations   *except  for  Quebec   CADTH Common Drug Review
“I  am  very  aware  that  there  are  people  on  the  other  side  of  these   submissions.  There  are  families.  There  are  husbands,  wives,   partners,  children..…We  need  to  take  what  they’re  telling  us….  use   as  a  guiding  point  for  making  very  humane  decisions.”     Cate  Dobhran,  CDEC  public  member  2014  
“PaBent  input  is  valuable  because  they  can  tell  us  things  no-­‐one   else  can……  Their  prioriBes  are  not  someBmes  the  prioriBes  people   presume,  or  assume,  they  are.”      Frank  Gavin,  CDEC  public  member  
Expert  CommiDees  (CDEC,  pERC)     Pa>ent  input  presented,   used  in  delibera>ons  &   reflected  in   recommenda>ons     Use of patient input at CADTH CADTH  Review   Team  Pa>ent  input  used  to   inform  protocol  &  report   Public  Drug  Plans   Shared  with  plans  and   shared  at  www.cadth.ca  
Used to identify outcomes
Understand current therapies Eculizumab  for  aHUS,  CDEC  Record  of  Advice   Ro>go>ne  for  Idiopathic  Parkinson  Disease,     CDEC  Recommenda>on  
Understand expectations Pirfenidone    for  Idiopathic  Pulmonary  Fibrosis,  CDEC  Recommenda>on   Vimizim    for  Mucopolysaccharidosis  IVA,    CDEC  Recommenda>on  
Evolution & revolution •  2010: Patient Input to CDR begins •  2013: Individual patient input in absence of patient group (pilot) •  2013: Public web posting of full CDR clinical report, economic report & original patient input (Update 87) •  2013: Creation CADTH Patient Community Liaison Forum •  2014: Thank you feedback letters to patient groups begin •  2014: Adjustments to existing CDR process for drugs for rare diseases, including additional appropriate specialists (Update 103) •  2015: In-person & written consultations on CDR & pCODR alignment •  2015: Consultation CDR & pCODR Recommendations Framework (Update 114)
Patient involvement in scientific advice https://scientificadvice.cadth.ca/
Support for patient groups youtube.com/CADTHACMTS Pa>ent  Input  into  CADTH  Common  Drug  Review:   Video  Series   pCODR    &  CCAN’s  Guide  for  Pa>ent  Advocacy  Groups:   Strengthening  your  submission     Pa>ent  Engagement  in  HTA:    Using  Pa>ent   Perspec>ves  to  Frame  HTAs   Two  pa>ent  engagement  officers  at  CADTH,  available  to  answer  ques>ons   or  provide  guidance,    Sarah  Berglas  &  Tamara  Rader   CADTH Patient Community Liaison Forum, including CORD
Embrace evolving successes in patient engagement practices in health technology assessment. Implement greater transparency regarding methods, performance, impact, and projects in development. Create ongoing process efficiencies to meet the demand for drug reviews and optimal use projects.
@CADTH_ACMTS linkedin.com/company/cadth slideshare.net/CADTH-ACMTS youtube.com/CADTHACMTS cadth.ca/photoblog requests@cadth.ca Connect with us

Recommended

Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Patient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionPatient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionCanadian Organization for Rare Disorders
 
David page cord standards of care 05 03-2015
David page cord standards of care 05 03-2015David page cord standards of care 05 03-2015
David page cord standards of care 05 03-2015Canadian Organization for Rare Disorders
 
Cathy parker the orphan drug framework
Cathy parker the orphan drug frameworkCathy parker the orphan drug framework
Cathy parker the orphan drug frameworkCanadian Organization for Rare Disorders
 
Hta barriers to ideal
Hta barriers to idealHta barriers to ideal
Hta barriers to idealCanadian Organization for Rare Disorders
 
Vers une Stratégie québécoise en matière de maladies rares
Vers une Stratégie québécoise en matière de maladies raresVers une Stratégie québécoise en matière de maladies rares
Vers une Stratégie québécoise en matière de maladies raresCanadian Organization for Rare Disorders
 
Glenn Monteith expert patients forum
Glenn Monteith expert patients forumGlenn Monteith expert patients forum
Glenn Monteith expert patients forumCanadian Organization for Rare Disorders
 
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...Canadian Organization for Rare Disorders
 

Recommended

Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Patient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionPatient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionCanadian Organization for Rare Disorders
 
David page cord standards of care 05 03-2015
David page cord standards of care 05 03-2015David page cord standards of care 05 03-2015
David page cord standards of care 05 03-2015Canadian Organization for Rare Disorders
 
Cathy parker the orphan drug framework
Cathy parker the orphan drug frameworkCathy parker the orphan drug framework
Cathy parker the orphan drug frameworkCanadian Organization for Rare Disorders
 
Hta barriers to ideal
Hta barriers to idealHta barriers to ideal
Hta barriers to idealCanadian Organization for Rare Disorders
 
Vers une Stratégie québécoise en matière de maladies rares
Vers une Stratégie québécoise en matière de maladies raresVers une Stratégie québécoise en matière de maladies rares
Vers une Stratégie québécoise en matière de maladies raresCanadian Organization for Rare Disorders
 
Glenn Monteith expert patients forum
Glenn Monteith expert patients forumGlenn Monteith expert patients forum
Glenn Monteith expert patients forumCanadian Organization for Rare Disorders
 
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...Canadian Organization for Rare Disorders
 
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...Canadian Organization for Rare Disorders
 
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview Canadian Organization for Rare Disorders
 
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Canadian Organization for Rare Disorders
 
RWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarRWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarCanadian Organization for Rare Disorders
 
Patient Centered Health Care Advocacy
Patient Centered Health Care AdvocacyPatient Centered Health Care Advocacy
Patient Centered Health Care AdvocacyCanadian Organization for Rare Disorders
 
CORD Rare Disease Patient Survey
CORD Rare Disease Patient SurveyCORD Rare Disease Patient Survey
CORD Rare Disease Patient SurveyCanadian Organization for Rare Disorders
 
Michael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation finalMichael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation finalCanadian Organization for Rare Disorders
 
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Canadian Organization for Rare Disorders
 
The Scleroderma Patient-centered Intervention Network: SPIN
The Scleroderma Patient-centered Intervention Network: SPINThe Scleroderma Patient-centered Intervention Network: SPIN
The Scleroderma Patient-centered Intervention Network: SPINCanadian Organization for Rare Disorders
 
IRDiRC: progress and expectations
IRDiRC: progress and expectationsIRDiRC: progress and expectations
IRDiRC: progress and expectationsCanadian Organization for Rare Disorders
 
A Brief History of the CDFI
A Brief History of the CDFIA Brief History of the CDFI
A Brief History of the CDFICanadian Organization for Rare Disorders
 
Durhane: Rare Drug Strategy Webinar
Durhane: Rare Drug Strategy WebinarDurhane: Rare Drug Strategy Webinar
Durhane: Rare Drug Strategy WebinarCanadian Organization for Rare Disorders
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...Canadian Organization for Rare Disorders
 
Webinar: Learnings and Unresolved Issues
Webinar: Learnings and Unresolved IssuesWebinar: Learnings and Unresolved Issues
Webinar: Learnings and Unresolved IssuesCanadian Organization for Rare Disorders
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveCanadian Organization for Rare Disorders
 
Patient Group Development and Engagement
Patient Group Development and EngagementPatient Group Development and Engagement
Patient Group Development and EngagementCanadian Organization for Rare Disorders
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015Canadian Organization for Rare Disorders
 
Barbara Sabourin regulating drugs in canada v2
Barbara Sabourin regulating drugs in canada v2Barbara Sabourin regulating drugs in canada v2
Barbara Sabourin regulating drugs in canada v2Canadian Organization for Rare Disorders
 
Strategy for Rare Diseases in Canada Where are we now? What else is needed?
Strategy for Rare Diseases in Canada Where are we now? What else is needed? Strategy for Rare Diseases in Canada Where are we now? What else is needed?
Strategy for Rare Diseases in Canada Where are we now? What else is needed? Canadian Organization for Rare Disorders
 
Rd managed access cases 2015
Rd managed access cases 2015Rd managed access cases 2015
Rd managed access cases 2015Canadian Organization for Rare Disorders
 
Dave Wilkinson: Rare Disease Day 2016 Conference
Dave Wilkinson: Rare Disease Day 2016 Conference Dave Wilkinson: Rare Disease Day 2016 Conference
Dave Wilkinson: Rare Disease Day 2016 Conference Canadian Organization for Rare Disorders
 

More Related Content

What's hot

Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...Canadian Organization for Rare Disorders
 
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Canadian Organization for Rare Disorders
 
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Canadian Organization for Rare Disorders
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...Canadian Organization for Rare Disorders
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Strategy for Rare Diseases in Canada Where are we now? What else is needed?
Strategy for Rare Diseases in Canada Where are we now? What else is needed? Strategy for Rare Diseases in Canada Where are we now? What else is needed?
Strategy for Rare Diseases in Canada Where are we now? What else is needed? Canadian Organization for Rare Disorders
 

What's hot (20)

Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
Clinical Trials on Repurposed Treatments for Immediate Incorporation into Cli...
 
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
Durhane Wong-Rieger (CORD) Canada's Rare Disease Strategy Brief Overview
 
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
 
RWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs WebinarRWD/RWE for Rare Disease Drugs Webinar
RWD/RWE for Rare Disease Drugs Webinar
 
Patient Centered Health Care Advocacy
Patient Centered Health Care AdvocacyPatient Centered Health Care Advocacy
Patient Centered Health Care Advocacy
 
CORD Rare Disease Patient Survey
CORD Rare Disease Patient SurveyCORD Rare Disease Patient Survey
CORD Rare Disease Patient Survey
 
Michael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation finalMichael reilly toronto nov19presentation final
Michael reilly toronto nov19presentation final
 
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
 
The Scleroderma Patient-centered Intervention Network: SPIN
The Scleroderma Patient-centered Intervention Network: SPINThe Scleroderma Patient-centered Intervention Network: SPIN
The Scleroderma Patient-centered Intervention Network: SPIN
 
IRDiRC: progress and expectations
IRDiRC: progress and expectationsIRDiRC: progress and expectations
IRDiRC: progress and expectations
 
A Brief History of the CDFI
A Brief History of the CDFIA Brief History of the CDFI
A Brief History of the CDFI
 
Durhane: Rare Drug Strategy Webinar
Durhane: Rare Drug Strategy WebinarDurhane: Rare Drug Strategy Webinar
Durhane: Rare Drug Strategy Webinar
 
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
STREAM ONE: Donna Wall, Bone marrow as a Vehicle for Correction of Rare Disor...
 
Webinar: Learnings and Unresolved Issues
Webinar: Learnings and Unresolved IssuesWebinar: Learnings and Unresolved Issues
Webinar: Learnings and Unresolved Issues
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
 
Patient Group Development and Engagement
Patient Group Development and EngagementPatient Group Development and Engagement
Patient Group Development and Engagement
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015Case study cdr p cpa re kuvan for cord november 2015
Case study cdr p cpa re kuvan for cord november 2015
 
Barbara Sabourin regulating drugs in canada v2
Barbara Sabourin regulating drugs in canada v2Barbara Sabourin regulating drugs in canada v2
Barbara Sabourin regulating drugs in canada v2
 
Strategy for Rare Diseases in Canada Where are we now? What else is needed?
Strategy for Rare Diseases in Canada Where are we now? What else is needed? Strategy for Rare Diseases in Canada Where are we now? What else is needed?
Strategy for Rare Diseases in Canada Where are we now? What else is needed?
 

Viewers also liked

Viewers also liked (20)

Rd managed access cases 2015
Rd managed access cases 2015Rd managed access cases 2015
Rd managed access cases 2015
 
Dave Wilkinson: Rare Disease Day 2016 Conference
Dave Wilkinson: Rare Disease Day 2016 Conference Dave Wilkinson: Rare Disease Day 2016 Conference
Dave Wilkinson: Rare Disease Day 2016 Conference
 
Jeff Biggs patient groups november 2015
Jeff Biggs patient groups november 2015Jeff Biggs patient groups november 2015
Jeff Biggs patient groups november 2015
 
EFFECTIVE GOVERNANCE Managing Board and Staff Roles
EFFECTIVE GOVERNANCE Managing Board and Staff RolesEFFECTIVE GOVERNANCE Managing Board and Staff Roles
EFFECTIVE GOVERNANCE Managing Board and Staff Roles
 
Rare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s whatRare Disorders Policies in Canada: Who’s who and what’s what
Rare Disorders Policies in Canada: Who’s who and what’s what
 
Kym Boycott: Rare Disease Day 2016 Conference
Kym Boycott: Rare Disease Day 2016 Conference Kym Boycott: Rare Disease Day 2016 Conference
Kym Boycott: Rare Disease Day 2016 Conference
 
Health Coach Brief Overview
Health Coach Brief OverviewHealth Coach Brief Overview
Health Coach Brief Overview
 
Managed entry agreement
Managed entry agreementManaged entry agreement
Managed entry agreement
 
Susa Benseler: Rare Disease Day 2016 Conference
Susa Benseler: Rare Disease Day 2016 Conference Susa Benseler: Rare Disease Day 2016 Conference
Susa Benseler: Rare Disease Day 2016 Conference
 
Safina Adatia: Rare Disease Day 2016 Conference
Safina Adatia: Rare Disease Day 2016 Conference Safina Adatia: Rare Disease Day 2016 Conference
Safina Adatia: Rare Disease Day 2016 Conference
 
How To Become An IEP Champion
How To Become An IEP ChampionHow To Become An IEP Champion
How To Become An IEP Champion
 
Hta basic introduction
Hta basic introductionHta basic introduction
Hta basic introduction
 
David King: Rare Disease Day 2016 Conference
David King: Rare Disease Day 2016 Conference David King: Rare Disease Day 2016 Conference
David King: Rare Disease Day 2016 Conference
 
Dr. Thombs: Rare Disease Day 2016 Conference
Dr. Thombs: Rare Disease Day 2016 Conference Dr. Thombs: Rare Disease Day 2016 Conference
Dr. Thombs: Rare Disease Day 2016 Conference
 
Innovative Medicines Canada (IMC) Consultations –
Innovative Medicines Canada (IMC) Consultations –Innovative Medicines Canada (IMC) Consultations –
Innovative Medicines Canada (IMC) Consultations –
 
LeAnne Bloedon (Aegerion) Rare Disease Day 2016 Conference
LeAnne Bloedon (Aegerion) Rare Disease Day 2016 Conference LeAnne Bloedon (Aegerion) Rare Disease Day 2016 Conference
LeAnne Bloedon (Aegerion) Rare Disease Day 2016 Conference
 
Jay Onysko: Rare Disease Day 2016 Conference
Jay Onysko: Rare Disease Day 2016 Conference Jay Onysko: Rare Disease Day 2016 Conference
Jay Onysko: Rare Disease Day 2016 Conference
 
George Wyatt: Rare Disease Day 2016 Conference
George Wyatt: Rare Disease Day 2016 Conference George Wyatt: Rare Disease Day 2016 Conference
George Wyatt: Rare Disease Day 2016 Conference
 
Sandra Anderson: Rare Disease Day 2016 Conference
Sandra Anderson: Rare Disease Day 2016 Conference Sandra Anderson: Rare Disease Day 2016 Conference
Sandra Anderson: Rare Disease Day 2016 Conference
 
Developing an Orphan Drug in Canada: Rare Disease Day 2016 Conference
Developing an Orphan Drug in Canada: Rare Disease Day 2016 Conference Developing an Orphan Drug in Canada: Rare Disease Day 2016 Conference
Developing an Orphan Drug in Canada: Rare Disease Day 2016 Conference
 

Similar to Chander slides november 19 20 2015-toronto

What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?Canadian Cancer Survivor Network
 
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesPan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesCanadian Organization for Rare Disorders
 
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...Canadian Organization for Rare Disorders
 
How patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval processHow patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval processCanadian Cancer Survivor Network
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Canadian Organization for Rare Disorders
 
How Canada's health technology assessment system can change to better meet pa...
How Canada's health technology assessment system can change to better meet pa...How Canada's health technology assessment system can change to better meet pa...
How Canada's health technology assessment system can change to better meet pa...Canadian Cancer Survivor Network
 
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...Canadian Organization for Rare Disorders
 
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationChallenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationCanadian Cancer Survivor Network
 
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?Jackie Brusch
 
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...Canadian Cancer Survivor Network
 
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Canadian Organization for Rare Disorders
 
Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...Canadian Organization for Rare Disorders
 
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016ipposi
 

Similar to Chander slides november 19 20 2015-toronto (20)

What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?What is patient engagement at CADTH, and how can you get involved?
What is patient engagement at CADTH, and how can you get involved?
 
Jornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy CliffordJornadas #PatientInHTA · Tammy Clifford
Jornadas #PatientInHTA · Tammy Clifford
 
CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?CADTH - Why it is important, and what now?
CADTH - Why it is important, and what now?
 
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesPan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
 
Patient Engagement in Drug Review: Helen Mai (CADTH)
Patient Engagement in Drug Review: Helen Mai (CADTH)Patient Engagement in Drug Review: Helen Mai (CADTH)
Patient Engagement in Drug Review: Helen Mai (CADTH)
 
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
July 16 Webinar 2: What we heard and what we didn’t hear at the PMPRB Public ...
 
How patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval processHow patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval process
 
Shared Decision Making in Health in Catalonia
Shared Decision Making in Health in CataloniaShared Decision Making in Health in Catalonia
Shared Decision Making in Health in Catalonia
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
 
RDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-RiegerRDD 2020 Day 1 AM - Durhane Wong-Rieger
RDD 2020 Day 1 AM - Durhane Wong-Rieger
 
How Canada's health technology assessment system can change to better meet pa...
How Canada's health technology assessment system can change to better meet pa...How Canada's health technology assessment system can change to better meet pa...
How Canada's health technology assessment system can change to better meet pa...
 
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
Rare Disease Patient Registries: Key to Drug Development and Access Webinar ...
 
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationChallenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and Innovation
 
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?
 
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
Bringing Rare Disease Drugs to Canada Opportunities, Challenges, and More Cha...
 
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
Incorporating Patient Preferences Into the HTA Deliberative Framework: The Pa...
 
Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...Does Canada need an Orphan Drug Policy to incentivize drug development and su...
Does Canada need an Orphan Drug Policy to incentivize drug development and su...
 
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & ValueHepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
 
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
PMI Masterclass - Derick Mitchell IPPOSI - October 19th 2016
 
Role of Patient Engagement in Healthcare Decision Making!
Role of Patient Engagement in Healthcare Decision Making!Role of Patient Engagement in Healthcare Decision Making!
Role of Patient Engagement in Healthcare Decision Making!
 

More from Canadian Organization for Rare Disorders

Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research NetworkDay 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research NetworkCanadian Organization for Rare Disorders
 
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of ManitobaDay 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of ManitobaCanadian Organization for Rare Disorders
 
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...Canadian Organization for Rare Disorders
 
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...Canadian Organization for Rare Disorders
 
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...Canadian Organization for Rare Disorders
 

More from Canadian Organization for Rare Disorders (20)

Webinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
Webinar: Investing $1.5b in A Sustainable Rare Disease EcosystemWebinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
Webinar: Investing $1.5b in A Sustainable Rare Disease Ecosystem
 
CORD-RQMO: English Slides
CORD-RQMO: English Slides CORD-RQMO: English Slides
CORD-RQMO: English Slides
 
CORD-RQMO: French Slides
CORD-RQMO: French SlidesCORD-RQMO: French Slides
CORD-RQMO: French Slides
 
Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases
Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases
Webinar: PMPRB NEW Guidelines and Impact on Rare Diseases
 
Day 1: NORD Centres of Excellence - Pamela Gavin
Day 1: NORD Centres of Excellence - Pamela GavinDay 1: NORD Centres of Excellence - Pamela Gavin
Day 1: NORD Centres of Excellence - Pamela Gavin
 
Day 1: IAM RARE: Pamela Gavin, NORD
Day 1: IAM RARE: Pamela Gavin, NORDDay 1: IAM RARE: Pamela Gavin, NORD
Day 1: IAM RARE: Pamela Gavin, NORD
 
Day 2: Rare Disease & Drug Access Pathway
Day 2: Rare Disease & Drug Access Pathway Day 2: Rare Disease & Drug Access Pathway
Day 2: Rare Disease & Drug Access Pathway
 
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research NetworkDay 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
Day 2: Thierry Lacaze-Masmonteil, Maternal Infant Child Youth Research Network
 
Dar 2: Patient Engagement and Patient Empowerment Panel
Dar 2: Patient Engagement and Patient Empowerment Panel Dar 2: Patient Engagement and Patient Empowerment Panel
Dar 2: Patient Engagement and Patient Empowerment Panel
 
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of ManitobaDay 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
Day 2: Cheryl Greenberg, Children's Hospital Research Institute of Manitoba
 
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
Day 1: INFORM RARE: Beth Potter, Alexandra Wyatt, Pranesh Chakraborty, Monica...
 
Day 1: Newborn Screening: Pranesh Chakraborty, University of Ottawa
Day 1: Newborn Screening: Pranesh Chakraborty, University of OttawaDay 1: Newborn Screening: Pranesh Chakraborty, University of Ottawa
Day 1: Newborn Screening: Pranesh Chakraborty, University of Ottawa
 
Day 1: Phenotypes: Orion Buske, PhenoTips
Day 1: Phenotypes: Orion Buske, PhenoTipsDay 1: Phenotypes: Orion Buske, PhenoTips
Day 1: Phenotypes: Orion Buske, PhenoTips
 
Day 1: Genomic Sequencing: Kym Boycott, CHEO
Day 1: Genomic Sequencing: Kym Boycott, CHEODay 1: Genomic Sequencing: Kym Boycott, CHEO
Day 1: Genomic Sequencing: Kym Boycott, CHEO
 
Day 1: INFORM RARE
Day 1: INFORM RAREDay 1: INFORM RARE
Day 1: INFORM RARE
 
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
Day 1 : Canadian Neuromuscular Network, Western University - Craig Campbell, ...
 
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
Day 1: Rare Disease Research Network and National Children’s Hospital - Marsh...
 
Day 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
Day 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDISDay 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
Day 1: WHO-RDI Global Rare Disease Network - Matt Bolz-Johnson, EURORDIS
 
Day 1: Children's Healthcare Canada CORD
Day 1: Children's Healthcare Canada CORD Day 1: Children's Healthcare Canada CORD
Day 1: Children's Healthcare Canada CORD
 
Day 1: Network of Centres of Excellence
Day 1: Network of Centres of ExcellenceDay 1: Network of Centres of Excellence
Day 1: Network of Centres of Excellence
 

Recently uploaded

EDUROOT SME_ Performance upto March-2024.pptx
EDUROOT SME_ Performance upto March-2024.pptxEDUROOT SME_ Performance upto March-2024.pptx
EDUROOT SME_ Performance upto March-2024.pptxaaryamanorathofficia
 
High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...
High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...
High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...narwatsonia7
 
VIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With Room
VIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With RoomVIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With Room
VIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With Roomishabajaj13
 
Cunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile Service
Cunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile ServiceCunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile Service
Cunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile ServiceHigh Profile Call Girls
 
VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...
VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...
VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...Garima Khatri
 
How the Congressional Budget Office Assists Lawmakers
How the Congressional Budget Office Assists LawmakersHow the Congressional Budget Office Assists Lawmakers
How the Congressional Budget Office Assists LawmakersCongressional Budget Office
 
VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...
VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...
VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...Suhani Kapoor
 
Call Girls Bangalore Saanvi 7001305949 Independent Escort Service Bangalore
Call Girls Bangalore Saanvi 7001305949 Independent Escort Service BangaloreCall Girls Bangalore Saanvi 7001305949 Independent Escort Service Bangalore
Call Girls Bangalore Saanvi 7001305949 Independent Escort Service Bangalorenarwatsonia7
 
(多少钱)Dal毕业证国外本科学位证
(多少钱)Dal毕业证国外本科学位证(多少钱)Dal毕业证国外本科学位证
(多少钱)Dal毕业证国外本科学位证mbetknu
 
(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service
(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service
(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Serviceranjana rawat
 
Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…
Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…
Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…nishakur201
 
DNV publication: China Energy Transition Outlook 2024
DNV publication: China Energy Transition Outlook 2024DNV publication: China Energy Transition Outlook 2024
DNV publication: China Energy Transition Outlook 2024Energy for One World
 
WORLD CREATIVITY AND INNOVATION DAY 2024.
WORLD CREATIVITY AND INNOVATION DAY 2024.WORLD CREATIVITY AND INNOVATION DAY 2024.
WORLD CREATIVITY AND INNOVATION DAY 2024.Christina Parmionova
 
Earth Day 2024 - AMC "COMMON GROUND'' movie night.
Earth Day 2024 - AMC "COMMON GROUND'' movie night.Earth Day 2024 - AMC "COMMON GROUND'' movie night.
Earth Day 2024 - AMC "COMMON GROUND'' movie night.Christina Parmionova
 
Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...
Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...
Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...ankitnayak356677
 
##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number
##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number
##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up NumberMs Riya
 
Precarious profits? Why firms use insecure contracts, and what would change t...
Precarious profits? Why firms use insecure contracts, and what would change t...Precarious profits? Why firms use insecure contracts, and what would change t...
Precarious profits? Why firms use insecure contracts, and what would change t...ResolutionFoundation
 
(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts
(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts
(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escortsranjana rawat
 

Recently uploaded (20)

EDUROOT SME_ Performance upto March-2024.pptx
EDUROOT SME_ Performance upto March-2024.pptxEDUROOT SME_ Performance upto March-2024.pptx
EDUROOT SME_ Performance upto March-2024.pptx
 
High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...
High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...
High Class Call Girls Bangalore Komal 7001305949 Independent Escort Service B...
 
The Federal Budget and Health Care Policy
The Federal Budget and Health Care PolicyThe Federal Budget and Health Care Policy
The Federal Budget and Health Care Policy
 
VIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With Room
VIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With RoomVIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With Room
VIP Kolkata Call Girl Jatin Das Park 👉 8250192130 Available With Room
 
Cunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile Service
Cunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile ServiceCunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile Service
Cunningham Road Call Girls Bangalore WhatsApp 8250192130 High Profile Service
 
VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...
VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...
VIP Mumbai Call Girls Andheri West Just Call 9920874524 with A/C Room Cash on...
 
How the Congressional Budget Office Assists Lawmakers
How the Congressional Budget Office Assists LawmakersHow the Congressional Budget Office Assists Lawmakers
How the Congressional Budget Office Assists Lawmakers
 
VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...
VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...
VIP Call Girls Service Bikaner Aishwarya 8250192130 Independent Escort Servic...
 
Call Girls Bangalore Saanvi 7001305949 Independent Escort Service Bangalore
Call Girls Bangalore Saanvi 7001305949 Independent Escort Service BangaloreCall Girls Bangalore Saanvi 7001305949 Independent Escort Service Bangalore
Call Girls Bangalore Saanvi 7001305949 Independent Escort Service Bangalore
 
(多少钱)Dal毕业证国外本科学位证
(多少钱)Dal毕业证国外本科学位证(多少钱)Dal毕业证国外本科学位证
(多少钱)Dal毕业证国外本科学位证
 
Call Girls In Rohini ꧁❤ 🔝 9953056974🔝❤꧂ Escort ServiCe
Call Girls In Rohini ꧁❤ 🔝 9953056974🔝❤꧂ Escort ServiCeCall Girls In Rohini ꧁❤ 🔝 9953056974🔝❤꧂ Escort ServiCe
Call Girls In Rohini ꧁❤ 🔝 9953056974🔝❤꧂ Escort ServiCe
 
(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service
(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service
(PRIYA) Call Girls Rajgurunagar ( 7001035870 ) HI-Fi Pune Escorts Service
 
Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…
Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…
Goa Escorts WhatsApp Number South Goa Call Girl … 8588052666…
 
DNV publication: China Energy Transition Outlook 2024
DNV publication: China Energy Transition Outlook 2024DNV publication: China Energy Transition Outlook 2024
DNV publication: China Energy Transition Outlook 2024
 
WORLD CREATIVITY AND INNOVATION DAY 2024.
WORLD CREATIVITY AND INNOVATION DAY 2024.WORLD CREATIVITY AND INNOVATION DAY 2024.
WORLD CREATIVITY AND INNOVATION DAY 2024.
 
Earth Day 2024 - AMC "COMMON GROUND'' movie night.
Earth Day 2024 - AMC "COMMON GROUND'' movie night.Earth Day 2024 - AMC "COMMON GROUND'' movie night.
Earth Day 2024 - AMC "COMMON GROUND'' movie night.
 
Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...
Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...
Greater Noida Call Girls 9711199012 WhatsApp No 24x7 Vip Escorts in Greater N...
 
##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number
##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number
##9711199012 Call Girls Delhi Rs-5000 UpTo 10 K Hauz Khas Whats Up Number
 
Precarious profits? Why firms use insecure contracts, and what would change t...
Precarious profits? Why firms use insecure contracts, and what would change t...Precarious profits? Why firms use insecure contracts, and what would change t...
Precarious profits? Why firms use insecure contracts, and what would change t...
 
(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts
(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts
(NEHA) Bhosari Call Girls Just Call 7001035870 [ Cash on Delivery ] Pune Escorts
 

Chander slides november 19 20 2015-toronto

  • 1. Expert Patient Advocates & 21st Century Therapies Forum TORONTO NOVEMBER 19-20, 2015 CHANDER SEHGAL, MD, MBA DIRECTOR, CDR AND OPTIMAL USE
  • 2. Role of CADTH Health  Canada  asks:   Is  it  safe?  Does  it   work?   Patented  Medicine  Prices     Review  Board  asks:   Is  the  price  excessive   compared  to  other   developed  countries?     CADTH  asks:    How  does  it   compare  to   exis>ng     treatment  op>ons?   Federal,   provincial  &   territorial  health   bodies  ask:   Can  we  afford   it?    
  • 3. 18 publicly funded drug plans serving  7.8  million  people   1 pan-Canadian* process: Conducting reviews of the clinical, cost-effectiveness, and patient group input for drugs Providing evidence-based formulary listing recommendations   *except  for  Quebec   CADTH Common Drug Review
  • 4. “I  am  very  aware  that  there  are  people  on  the  other  side  of  these   submissions.  There  are  families.  There  are  husbands,  wives,   partners,  children..…We  need  to  take  what  they’re  telling  us….  use   as  a  guiding  point  for  making  very  humane  decisions.”     Cate  Dobhran,  CDEC  public  member  2014  
  • 5. “PaBent  input  is  valuable  because  they  can  tell  us  things  no-­‐one   else  can……  Their  prioriBes  are  not  someBmes  the  prioriBes  people   presume,  or  assume,  they  are.”      Frank  Gavin,  CDEC  public  member  
  • 6. Expert  CommiDees  (CDEC,  pERC)     Pa>ent  input  presented,   used  in  delibera>ons  &   reflected  in   recommenda>ons     Use of patient input at CADTH CADTH  Review   Team  Pa>ent  input  used  to   inform  protocol  &  report   Public  Drug  Plans   Shared  with  plans  and   shared  at  www.cadth.ca  
  • 7. Used to identify outcomes
  • 8. Understand current therapies Eculizumab  for  aHUS,  CDEC  Record  of  Advice   Ro>go>ne  for  Idiopathic  Parkinson  Disease,     CDEC  Recommenda>on  
  • 9. Understand expectations Pirfenidone    for  Idiopathic  Pulmonary  Fibrosis,  CDEC  Recommenda>on   Vimizim    for  Mucopolysaccharidosis  IVA,    CDEC  Recommenda>on  
  • 10. Evolution & revolution •  2010: Patient Input to CDR begins •  2013: Individual patient input in absence of patient group (pilot) •  2013: Public web posting of full CDR clinical report, economic report & original patient input (Update 87) •  2013: Creation CADTH Patient Community Liaison Forum •  2014: Thank you feedback letters to patient groups begin •  2014: Adjustments to existing CDR process for drugs for rare diseases, including additional appropriate specialists (Update 103) •  2015: In-person & written consultations on CDR & pCODR alignment •  2015: Consultation CDR & pCODR Recommendations Framework (Update 114)
  • 11. Patient involvement in scientific advice https://scientificadvice.cadth.ca/
  • 12. Support for patient groups youtube.com/CADTHACMTS Pa>ent  Input  into  CADTH  Common  Drug  Review:   Video  Series   pCODR    &  CCAN’s  Guide  for  Pa>ent  Advocacy  Groups:   Strengthening  your  submission     Pa>ent  Engagement  in  HTA:    Using  Pa>ent   Perspec>ves  to  Frame  HTAs   Two  pa>ent  engagement  officers  at  CADTH,  available  to  answer  ques>ons   or  provide  guidance,    Sarah  Berglas  &  Tamara  Rader   CADTH Patient Community Liaison Forum, including CORD
  • 13. Embrace evolving successes in patient engagement practices in health technology assessment. Implement greater transparency regarding methods, performance, impact, and projects in development. Create ongoing process efficiencies to meet the demand for drug reviews and optimal use projects.